600420.SS
Shanghai Shyndec Pharmaceutical Co., Ltd. [600420.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600420.SS Stock Summary
Top 10 Correlated Stocks
600420.SS
In the News
600420.SS Financial details
Company Rating
Buy
Market Cap
12.54B
Income
363.2M
Revenue
12.95B
Book val./share
8.68
Cash/share
4.27
Dividend
0.1
Dividend %
0.95%
Employees
11.94K
Optionable
No
Shortable
Yes
Earnings
29 Apr 2022
P/E
29.71
Forward P/E
-
PEG
-6.75
P/S
0.83
P/B
1.21
P/C
2.45
P/FCF
6.4
Quick Ratio
0.96
Current Ratio
2.31
Debt / Equity
0.87
LT Debt / Equity
0.33
-
-
EPS (TTM)
0.35
EPS next Y
-
EPS next Q
-
EPS this Y
-12.41%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
3.55%
Revenue last 5Y
10.36%
Revenue Q/Q
6.02%
EPS Q/Q
36.89%
-
-
-
-
SMA20
1.86%
SMA50
13.04%
SMA100
17.38%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
4%
ROC
0.05%
Gross Margin
40%
Oper. Margin
6%
Profit Margin
3%
Payout
72%
Shs Outstand
1.17B
Shs Float
353.48M
-
-
-
-
Target Price
-
52W Range
8.24-12.8
52W High
-12.75%
52W Low
+30.88%
RSI
55.83
Rel Volume
0.51
Avg Volume
11.86M
Volume
6.05M
Perf Week
2.15%
Perf Month
6.19%
Perf Quarter
20.62%
Perf Half Y
21.04%
-
-
-
-
Beta
0.238209
-
-
Volatility
0.2%, 0.18%
Prev Close
-0.1%
Price
10.47
Change
0.67%
600420.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 7.68 | 10.37 | 11.6 | 12.23 | 13.58 | |
| Net income per share | 0.46 | 0.65 | 0.62 | 0.63 | 0.55 | |
| Operating cash flow per share | 2.09 | 1.53 | 1.21 | 1.52 | 1.64 | |
| Free cash flow per share | 1.93 | 1.16 | 0.82 | 1.15 | 1.13 | |
| Cash per share | 2.2 | 3.51 | 4.91 | 3.62 | 4.17 | |
| Book value per share | 5.56 | 6.23 | 7.22 | 7.92 | 8.37 | |
| Tangible book value per share | 5.84 | 6.77 | 7.79 | 8.65 | 9.28 | |
| Share holders equity per share | 5.56 | 6.23 | 7.22 | 7.92 | 8.37 | |
| Interest debt per share | 3.92 | 3.61 | 4.27 | 3.18 | 3.59 | |
| Market cap | 14.12B | 9.45B | 9.4B | 9.77B | 10.65B | |
| Enterprise value | 15.78B | 9.35B | 8.53B | 9.19B | 9.94B | |
| P/E ratio | 27.37 | 13.39 | 14.32 | 15.05 | 18.74 | |
| Price to sales ratio | 1.66 | 0.83 | 0.77 | 0.78 | 0.76 | |
| POCF ratio | 6.1 | 5.66 | 7.4 | 6.26 | 6.34 | |
| PFCF ratio | 6.58 | 7.44 | 10.85 | 8.26 | 9.19 | |
| P/B Ratio | 2.29 | 1.39 | 1.24 | 1.2 | 1.24 | |
| PTB ratio | 2.29 | 1.39 | 1.24 | 1.2 | 1.24 | |
| EV to sales | 1.85 | 0.83 | 0.7 | 0.73 | 0.71 | |
| Enterprise value over EBITDA | 9.18 | 4.98 | 4.98 | 5.61 | 6.23 | |
| EV to operating cash flow | 6.82 | 5.6 | 6.72 | 5.89 | 5.92 | |
| EV to free cash flow | 7.35 | 7.36 | 9.85 | 7.78 | 8.58 | |
| Earnings yield | 0.04 | 0.07 | 0.07 | 0.07 | 0.05 | |
| Free cash flow yield | 0.15 | 0.13 | 0.09 | 0.12 | 0.11 | |
| Debt to equity | 1.22 | 1.18 | 1.11 | 1.04 | 1.01 | |
| Debt to assets | 0.5 | 0.49 | 0.48 | 0.46 | 0.46 | |
| Net debt to EBITDA | 0.97 | -0.05 | -0.51 | -0.35 | -0.44 | |
| Current ratio | 1.28 | 1.29 | 1.49 | 1.64 | 1.59 | |
| Interest coverage | 4.62 | 5.01 | 6.6 | 10.39 | 8.13 | |
| Income quality | 4.49 | 2.37 | 1.94 | 2.4 | 2.96 | |
| Dividend Yield | 0.03 | 0.05 | 0.03 | 0.02 | 0.02 | |
| Payout ratio | 0.77 | 0.65 | 0.49 | 0.32 | 0.37 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.04 | 0.03 | 0.03 | 0.04 | 0.04 | |
| Intangibles to total assets | 0.08 | 0.06 | 0.06 | 0.05 | 0.04 | |
| Capex to operating cash flow | -0.07 | -0.24 | -0.32 | -0.24 | -0.31 | |
| Capex to revenue | -0.02 | -0.04 | -0.03 | -0.03 | -0.04 | |
| Capex to depreciation | -0.21 | -0.55 | -0.56 | -0.52 | -0.64 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.63 | 9.52 | 10.07 | 10.61 | 10.21 | |
| ROIC | 0.11 | 0.13 | 0.19 | 0.13 | 0.09 | |
| Return on tangible assets | 0.04 | 0.05 | 0.04 | 0.04 | 0.03 | |
| Graham Net | -3.72 | -2.78 | -2.01 | -2.99 | -2.8 | |
| Working capital | 1.53B | 1.9B | 3.18B | 3.97B | 4.04B | |
| Tangible asset value | 6.48B | 7.39B | 8.19B | 8.88B | 9.53B | |
| Net current asset value | -602.89M | 449.61M | 1.24B | 1.73B | 2.19B | |
| Invested capital | 0.66 | 0.55 | 0.57 | 0.39 | 0.42 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.33B | 1.67B | 1.75B | 1.85B | 1.97B | |
| Average inventory | 1.86B | 2.12B | 2.32B | 2.8B | 3.18B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 99.53 | 127.98 | 87.71 | 122.39 | 79.61 | |
| Days of inventory on hand | 145.09 | 145.73 | 137.85 | 180.22 | 142.89 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 3.67 | 2.85 | 4.16 | 2.98 | 4.58 | |
| Inventory turnover | 2.52 | 2.5 | 2.65 | 2.03 | 2.55 | |
| ROE | 0.08 | 0.1 | 0.09 | 0.08 | 0.07 | |
| Capex per share | -0.15 | -0.37 | -0.38 | -0.37 | -0.51 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 3 | 3.15 | 3.16 | 3.06 | 3.24 | |
| Net income per share | 0.2 | -0.06 | 0.08 | 0.14 | 0.2 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0.79 | 0.19 | 0.28 | 0.79 | 0.61 | |
| Cash per share | 4.06 | 4.17 | 4.21 | 4.17 | 4.27 | |
| Book value per share | 8.43 | 8.37 | 8.44 | 8.49 | 8.68 | |
| Tangible book value per share | 9.26 | 9.28 | 9.42 | 9.42 | 9.59 | |
| Share holders equity per share | 8.43 | 8.37 | 8.44 | 8.49 | 8.68 | |
| Interest debt per share | 3.8 | 3.51 | 4.31 | 3.87 | 3.6 | |
| Market cap | 9.9B | 10.65B | 11.34B | 10.17B | 8.8B | |
| Enterprise value | 9.6B | 9.94B | 11.41B | 9.83B | 8.09B | |
| P/E ratio | 12.06 | -42.14 | 36.51 | 17.26 | 10.92 | |
| Price to sales ratio | 3.22 | 3.29 | 3.49 | 3.23 | 2.64 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 12.15 | 53.24 | 39.86 | 12.47 | 14.09 | |
| P/B Ratio | 1.14 | 1.24 | 1.31 | 1.17 | 0.99 | |
| PTB ratio | 1.14 | 1.24 | 1.31 | 1.17 | 0.99 | |
| EV to sales | 3.12 | 3.07 | 3.52 | 3.13 | 2.43 | |
| Enterprise value over EBITDA | 40.89 | -264.7 | 74.36 | 43.46 | 29.87 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 11.78 | 49.7 | 40.11 | 12.05 | 12.95 | |
| Earnings yield | 0.02 | -0.01 | 0.01 | 0.01 | 0.02 | |
| Free cash flow yield | 0.08 | 0.02 | 0.03 | 0.08 | 0.07 | |
| Debt to equity | 1.05 | 1.01 | 1.04 | 0.99 | 0.87 | |
| Debt to assets | 0.47 | 0.46 | 0.46 | 0.45 | 0.42 | |
| Net debt to EBITDA | -1.27 | 18.84 | 0.46 | -1.48 | -2.63 | |
| Current ratio | 1.55 | 1.59 | 1.84 | 2 | 2.31 | |
| Interest coverage | 7.39 | 1.35 | 6.07 | 8.29 | 11.83 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0.02 | |
| Payout ratio | 0.2 | -0.15 | 0.63 | 0.1 | 0.93 | |
| Sales general and administrative to revenue | 0.16 | -0.12 | 0.06 | -0.02 | 0.14 | |
| Research and developement to revenue | 0.05 | 0.06 | 0.04 | 0.04 | 0.04 | |
| Intangibles to total assets | 0.05 | 0.04 | 0.04 | 0.04 | 0.05 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.04 | -0.03 | -0.04 | -0.01 | -0.02 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.16 | 3.4 | 3.79 | 5.23 | 6.19 | |
| ROIC | 0.02 | 0 | 0.02 | 0.02 | 0.03 | |
| Return on tangible assets | 0.01 | 0 | 0 | 0.01 | 0.01 | |
| Graham Net | -3.16 | -2.8 | -3.05 | -2.7 | -1.96 | |
| Working capital | 4.02B | 4.04B | 5.22B | 5.58B | 6.01B | |
| Tangible asset value | 9.51B | 9.53B | 9.67B | 9.68B | 9.84B | |
| Net current asset value | 2.16B | 2.19B | 2.43B | 2.56B | 2.8B | |
| Invested capital | 0.45 | 0.42 | 0.51 | 0.45 | 0.41 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.23B | 1.81B | 1.9B | 2.02B | 1.8B | |
| Average inventory | 3.35B | 3.21B | 3.07B | 3.07B | 2.93B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 103.94 | 82.16 | 101.28 | 90.5 | 72.67 | |
| Days of inventory on hand | 182 | 147.46 | 148.54 | 142.65 | 122.3 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.87 | 1.1 | 0.89 | 0.99 | 1.24 | |
| Inventory turnover | 0.49 | 0.61 | 0.61 | 0.63 | 0.74 | |
| ROE | 0.02 | -0.01 | 0.01 | 0.02 | 0.02 | |
| Capex per share | -0.11 | -0.1 | -0.13 | -0.03 | -0.07 |
600420.SS Frequently Asked Questions
What is Shanghai Shyndec Pharmaceutical Co., Ltd. stock symbol ?
Shanghai Shyndec Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 600420.SS
What is Shanghai Shyndec Pharmaceutical Co., Ltd. stock quote today ?
Shanghai Shyndec Pharmaceutical Co., Ltd. stock price is $10.47 today.
Is Shanghai Shyndec Pharmaceutical Co., Ltd. stock public?
Yes, Shanghai Shyndec Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 11.86M
- Market Capitalization 12.54B
- Employee 11.94K
- CEO Mr. Bin Zhou
- Headquarters Shanghai,CN
- IPO Date 2004-06-16
-
Website
https://www.shyndec.com 
Shanghai Shyndec Pharmaceutical Co., Ltd. manufactures drug preparation products in China and internationally. It focuses on anti-infection, cardiovascular and cerebrovascular, anti-tumor, metabolism, and endocrine areas. The company was founded in 1996 and is based in Shanghai, China.
